top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
816_aicvd (8)_9_edited.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
f055739f-1956-41a1-8156-cda95d1fea9f.png
AI-CVD Bundle
Muscle and Fat Analysis.png
Liver Attenuation.png
Cardiac Chambers Volumetry.png
ٍEpicardial Fat .png
Bone Mineral Density (BMD) .png
coronaryArteryCalcification.png
Lung Density Report- High Attenuation Index.png
Thoracic Aorta and Pulmonary Artery Sizing .png
Aortic Wall Aortic and Mitral Valve Report.png
Lung Density Report- Low Attenuation Index.png
AI-CVD--.png
Frame 1000008286.png
Frame 1000008286.png

AI-CAC: Coronary Plaque Analysis from Non-Contrast CT

Jul 15
1 min read

Updated: Jul 17


AI-CAC introduces a novel artificial intelligence approach for coronary plaque analysis using non-contrast cardiac CT (CAC) scans, offering the potential to extract plaque characteristics traditionally obtainable only from contrast-enhanced coronary CT angiography (CCTA).

Conventional CCTA provides excellent visualization of coronary anatomy but requires intravenous contrast administration and is affected by scanner-, software-, and observer-related variability. AI-CAC addresses these limitations by applying advanced deep learning techniques to routine non-contrast CT scans, enabling detailed assessment of coronary plaque composition without the need for contrast agents.

The presented study validates AI-CAC against Cleerly AI-QCT using paired non-contrast CT and CCTA datasets from the Miami Heart Study. Results demonstrate strong agreement for multiple plaque measurements, including calcified plaque volume, total plaque volume, and lumen volume, highlighting the potential of AI-CAC as a practical and scalable alternative for coronary plaque assessment.

The presentation also introduces the next evolution of the platform—Virtual CCTA—an AI-driven technology capable of generating contrast-enhanced coronary images from standard non-contrast CT scans, opening new possibilities for accessible, lower-cost cardiovascular imaging and risk assessment.

Download the complete presentation below to explore the AI methodology, validation study, technical workflow, and the future vision of AI-CAC and Virtual CCTA.




Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page